--- title: "Pre-market hot trades in US stocks: Ucommune pre-market down 4.52%; ConocoPhillips pre-market down 4.26%" type: "News" locale: "en" url: "https://longbridge.com/en/news/285385880.md" description: "Ucommune pre-market down 4.52%; ConocoPhillips pre-market down 4.26%; Entravision Communications pre-market up 70.33%; Ambitions Enterprise pre-market up 54.56%; Avalo Therapeutics pre-market up 46.06%" datetime: "2026-05-06T13:17:36.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285385880.md) - [en](https://longbridge.com/en/news/285385880.md) - [zh-HK](https://longbridge.com/zh-HK/news/285385880.md) --- # Pre-market hot trades in US stocks: Ucommune pre-market down 4.52%; ConocoPhillips pre-market down 4.26% **Pre-market Hot Trades in US Stocks** Ucommune, down 4.52% in pre-market trading, has no significant news recently. The trading is active with clear capital flow, and considering the sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation. ConocoPhillips is down 4.26% in pre-market trading. Based on recent key news: 1. On May 5, ConocoPhillips announced its first-quarter earnings report, where adjusted earnings per share exceeded expectations, but revenue fell short, and net profit decreased by 23.13% year-on-year, leading to a negative market reaction. The company also announced a $1 billion stock buyback and raised its capital expenditure guidance to $12-12.5 billion. 2. On May 6, supply disruptions in the Middle East caused a surge in crude oil prices in Asia and the US, and the integration of the global refined oil market also put price pressure on the US market, further affecting ConocoPhillips' stock price. 3. On May 5, Norway's Ministry of Petroleum and Energy approved ConocoPhillips' redevelopment plan in the Ekofisk area, expected to start production in the fourth quarter of 2028, although this long-term positive news did not immediately boost the stock price. Global oil price fluctuations have intensified, increasing market uncertainty. **Top Gainers in Pre-market US Stocks** Entravision is up 70.33% in pre-market trading. Based on recent key news: 1. On May 5, Entravision released a strong first-quarter earnings report, showing a year-on-year revenue growth of 114.4%, reaching $196.97 million, driving a significant increase in stock price. The company's net income was $12.36 million, exceeding market expectations and further boosting investor confidence. Source: Reuters 2. On May 5, the company's CEO stated that 2026 will be an important year for political advertising spending, expecting significant revenue from gubernatorial campaigns in California, Nevada, and Texas. This expectation has fueled market optimism towards Entravision. Source: Reuters 3. On May 5, Entravision's stock received significant attention from retail traders, with bullish sentiment on social platforms significantly increasing, and trading volume also surged. Source: Reuters The expectation of political advertising spending drives industry growth. Ambitions Enterprise is up 54.56% in pre-market trading, with no significant news recently. The trading is active with clear capital flow, and considering the sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation. Avalo Therapeutics is up 46.06% in pre-market trading. Based on recent news, 1. On May 5, Avalo Therapeutics announced that its experimental drug abdakibart achieved its primary endpoint in a mid-stage trial for the treatment of chronic skin disease hidradenitis suppurativa. The drug helped approximately 42% of patients achieve significant skin clearance within 16 weeks, compared to only 25.6% of patients receiving a placebo This news drove the stock price up by 43%. 2. On May 5th, Avalo Therapeutics announced a public stock offering worth $375 million, which is expected to fund the further development of abdakibart. This news further boosted market confidence and drove the stock price up. 3. On May 5th, Avalo Therapeutics' stock rose by 48.5% in after-hours trading, mainly due to the successful drug trial and the news of the stock offering. Avalo Therapeutics has performed strongly recently, with significant capital inflows ### Related Stocks - [UK.US](https://longbridge.com/en/quote/UK.US.md) - [COP.US](https://longbridge.com/en/quote/COP.US.md) - [EVC.US](https://longbridge.com/en/quote/EVC.US.md) - [AHMA.US](https://longbridge.com/en/quote/AHMA.US.md) - [AVTX.US](https://longbridge.com/en/quote/AVTX.US.md) ## Related News & Research - [ConocoPhillips $COP Stake Lessened by Washington Trust Bank](https://longbridge.com/en/news/286090547.md) - [TBH Global Asset Management LLC Raises Position in ConocoPhillips $COP](https://longbridge.com/en/news/284079584.md) - [ACHR, JOBY: Cathie Wood Invests Nearly $3M in Air Taxi Stocks — Here's What Analysts Think](https://longbridge.com/en/news/286891045.md) - [A Look At Cigna Group (CI) Valuation As Guidance Rises And Rebate Free Pharmacy Launches](https://longbridge.com/en/news/286806396.md) - [NextEra slides 5% on Dominion megadeal but will shore up credit profile](https://longbridge.com/en/news/286814468.md)